Veru Inc. Files Proxy Materials
Ticker: VERU · Form: DEFA14A · Filed: Apr 1, 2024 · CIK: 863894
Sentiment: neutral
Topics: proxy-statement, corporate-governance
TL;DR
VERU proxy filing is in, shareholders get to vote on company stuff.
AI Summary
Veru Inc. filed a Definitive Additional Materials proxy statement on April 1, 2024. This filing relates to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company, previously known as The Female Health Co. and Wisconsin Pharmacal Company Inc., is incorporated in Wisconsin and headquartered in Miami, Florida.
Why It Matters
Proxy statements are crucial for shareholders to understand upcoming votes and company decisions, ensuring informed participation in corporate governance.
Risk Assessment
Risk Level: low — This filing is a standard proxy statement, indicating routine corporate governance activity rather than a significant event.
Key Players & Entities
- VERU INC. (company) — Registrant
- The Female Health Co. (company) — Former company name
- Wisconsin Pharmacal Company Inc (company) — Former company name
- April 1, 2024 (date) — Filing date
FAQ
What type of filing is this for Veru Inc.?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
When was this filing submitted?
The filing was submitted on April 1, 2024.
What are Veru Inc.'s previous company names?
Veru Inc. was formerly known as The Female Health Co. and Wisconsin Pharmacal Company Inc.
Where is Veru Inc. incorporated and headquartered?
Veru Inc. is incorporated in Wisconsin and its business address is in Miami, Florida.
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used to solicit shareholder votes on important corporate matters.
Filing Stats: 1,358 words · 5 min read · ~5 pages · Grade level 18.1 · Accepted 2024-04-01 16:31:58
Filing Documents
- d800436ddefa14a.htm (DEFA14A) — 20KB
- g800436g0330074954964.jpg (GRAPHIC) — 2KB
- 0001193125-24-083460.txt ( ) — 24KB
Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to whether and when the planned phase 2b trial of enobosarm discussed above will commence or produce topline data or patients will progress into the extension study, the planned design, timing, endpoints, patient population and patient size of such trial and whether such trial will successfully meet any of its endpoints, whether enobosarm will enhance weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will enhance weight loss, and whether the Company will be successful in its transformation into a late stage biopharmaceutical company focused on obesity and oncology. The words anticipate, believe, could, expect, intend, may, opportunity, plan, predict, potential, estimate, should, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Companys current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward- looking statements contained in this press release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include,